Kürşat Dal
Research Subjects
Research Interests
Kürşat Dal has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abdulkadir Basturk
Department of Hematology, Konya City Hospital, Konya 42120, Turkiye
1 shared publication - Burhan Turgut
Department of Hematology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdağ 59030, Turkey
1 shared publication - Fevzi Altuntaş
Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey
1 shared publication - Ilhami Berber
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
1 shared publication - Mehmet Ali Erkurt
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
1 shared publication - Mehmet Hilmi Dogu
Univ Hlth Sci Turkey, Istanbul Training & Res Hosp, Clin Hematol, Istanbul, Turkey
1 shared publication
Latest Publications
- 10 June 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (1) , 135-139
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
Previous studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course compared to the general population. However, no randomized study compared the clinical course of COVID-19 in patients with hematologic cancers to patients with solid cancers. Thus, in this study, we intend to reveal the outcome of COVID-19 in hematologic cancer patients and compare their outcomes with COVID-19 patients with solid cancers. The data of 926 laboratory-confirmed COVID-19 patients, including 463 hematologic cancer patients and an age-gender paired cohort of 463 solid cancer patients, were investigated retrospectively. The frequencies of severe and critical disease, hospital and ICU admission, MV assistance were significantly higher in hematologic cancer patients compared with the solid cancer patients (p = 0.001, p = 0.045, p = 0.001, and p = 0.001, respectively). The hospital stay was longer in patients with hematologic cancers (p = 0.001); however, the median ICU stay was 6 days in both groups. The case fatality rate (CFR) was 14.9% in patients with hematologic cancers, and it was 4.8% in patients with solid cancers, and there was a statistically significant difference regarding CFR between groups (p = 0.001). Our study revealed that COVID-19 patients with hematologic cancers have a more aggressive course of COVID-19 and have higher CFR compared to COVID-19 patients with solid cancers and support the increased susceptibility of patients with hematologic cancers during the outbreak.
- 10 June 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (1) , 135-139
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
Previous studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course compared to the general population. However, no randomized study compared the clinical course of COVID-19 in patients with hematologic cancers to patients with solid cancers. Thus, in this study, we intend to reveal the outcome of COVID-19 in hematologic cancer patients and compare their outcomes with COVID-19 patients with solid cancers. The data of 926 laboratory-confirmed COVID-19 patients, including 463 hematologic cancer patients and an age-gender paired cohort of 463 solid cancer patients, were investigated retrospectively. The frequencies of severe and critical disease, hospital and ICU admission, MV assistance were significantly higher in hematologic cancer patients compared with the solid cancer patients (p = 0.001, p = 0.045, p = 0.001, and p = 0.001, respectively). The hospital stay was longer in patients with hematologic cancers (p = 0.001); however, the median ICU stay was 6 days in both groups. The case fatality rate (CFR) was 14.9% in patients with hematologic cancers, and it was 4.8% in patients with solid cancers, and there was a statistically significant difference regarding CFR between groups (p = 0.001). Our study revealed that COVID-19 patients with hematologic cancers have a more aggressive course of COVID-19 and have higher CFR compared to COVID-19 patients with solid cancers and support the increased susceptibility of patients with hematologic cancers during the outbreak.